{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"Number of patients with skeletal-related events (i.e. pathological fracture (vertebral, non-vertebral, combined), radiotherapy, spinal cord compression, orthopaedic surgery, hypercalcaemia) occurring over 24 months study period","groups":[{"description":"bortezomib (Velcade) 1.6 mg/m² bolus injection on Days 1, 8, 15 and 22 every 5 weeks for 4 cycles","id":"OG000","title":"Bortezomib"},{"description":"no treatment, observation only","id":"OG001","title":"Non-treated Control"}],"paramType":"NUMBER","populationDescription":"FAS included all the randomized subjects who were eligible for efficacy analysis, that is, excluding subjects who did not have baseline and/or post-baseline data. \"N\" (number of subjects analyzed) signifies the subjects evaluable this measure.","reportingStatus":"POSTED","timeFrame":"Baseline up to end of study (approximately 4 years 7 months)","title":"Number of Patients With Skeletal Events","type":"SECONDARY","unitOfMeasure":"patients"}